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decade enabling the delivery of high radiation doses, 
reducing side-effects in tumour-adjacent normal tissues. 
While increasing local tumour control, current and future 
efforts ought to deal with microscopic disease at a distance 
of the primary tumour, ultimately responsible for disease-
progression. This talk will explores the possibility of bimodal 
treatment combining radiotherapy with immunotherapy. L19 
targets the extra domain B (ED-B) of fibronectin, a marker 
for tumor neoangiogenesis, and can be used as 
immunocytokine when coupled to IL2. We hypothesize that 
radiotherapy in combination with L19-IL2 provides an 
enhanced antitumor effect, which is dependent on ED-B 
expression.  
EXPERIMENTAL DESIGN: Mice were injected with syngeneic 
C51 colon carcinoma, Lewis lung carcinoma (LLC), or 4T1 
mammary carcinoma cells. Tumor growth delay, underlying 
immunologic parameters, and treatment toxicity were 
evaluated after single-dose local tumor irradiation and 
systemic administration of L19-IL2 or equimolar controls.  
RESULTS: ED-B expression was high, intermediate, and low 
for C51, LLC, and 4T1, respectively. The combination therapy 
showed (i) a long-lasting synergistic effect for the C51 model 
with 75% of tumors being cured, (ii) an additive effect for the 
LLC model, and (iii) no effect for the 4T1 model. The 
combination treatment resulted in a significantly increased 
cytotoxic (CD8(+)) T-cell population for both C51 and LLC. 
Depletion of CD8(+) T cells abolished the benefit of the 
combination therapy.  
CONCLUSIONS: These data provide the first evidence for an 
increased therapeutic potential by combining radiotherapy 
with L19-IL2 in ED-B-positive tumors. This new opportunity in 
cancer treatment will be investigated in a phase I clinical 
study for patients with an oligometastatic solid tumor 
(NCT02086721). An animation summarizing our results is 
available at 
https://www.youtube.com/watch?v=xHbwQuCTkRc .  
REFERENCE:. Zegers CM1, Rekers NH2, Quaden DH3, Lieuwes 
NG2, Yaromina A2, Germeraad WT4, Wieten L5, Biessen EA6, 
Boon L7, Neri D8, Troost EG2, Dubois LJ2, Lambin P2. 
Radiotherapy combined with the immunocytokine L19-IL2 
provides long-lasting antitumor effects. Clin Cancer Res. 2015 
Mar 1;21(5):1151-60. 
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For a number of tumour types there is increasing acceptance 
that cancer stem cells play an important role in tumour 
initiation and recurrence after treatment. In line with this 
model, increasing evidence indicates that cancer stem cells 
exhibit resistance to conventional cytotoxic agents. In the 
case of glioblastoma, an incurable primary brain tumour 
associated with dismal prognosis and devastating effects on 
quality of life, a series of influential publications have 
demonstrated that the radiation resistance of glioblastoma 
stem-like cells (GSC) is associated with constitutive 
upregulation of the DNA damage response (DDR).  
In this presentation I will outline the evidence supporting this 
model, and present new data that elucidates the relative 
contributions of DNA repair and cell cycle checkpoints to this 
phenotype. Subsequently I will investigate the effects of 
inhibiting various components of the DDR, alone and in 
combination, and discuss the potential clinical application of 
a number of promising new small molecule inhibitors. 
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Recent technological advances in DNA sequencing with 
greater speed and resolution at lower costs has provided new 
insights in cancer genetics. The next-generation sequencing 
(NGS) technology is tremendously facilitating the in-depth 
genome-wide search for genetic alterations which might 
significantly contribute to aggressive and/or treatment-
resistant phenotypes of cancers, thereby establishing the 
basis for improvement of cancer treatment. We hypothesized 
that NGS should also be useful for dissecting the molecular 
mechanisms of radioresistance in squamous cell carcinoma of 
the head and neck (HNSCC). 
We therefore applied the technology of targeted NGS to 
clinical samples from two multicenter studies of definitive 
and adjuvant cisplatin-based chemoradiation of locally 
advanced HNSCC. We evaluated whether by molecular 
profiling using targeted NGS it is possible to prospectively 
discriminate between patients who clearly benefit from 
chemoradiation and those with poor locoregional control and 
reduced overall survival after such treatment. Our studies 
could confirm previous reports of poor efficacy of 
radiotherapy in HNSCC tumors harboring TP53 mutations. For 
the first time, we identified additional mutations in other 
genes as predictive biomarkers of outcome after 
chemoradiation. 
The talk will summarize the results of NGS studies in HNSCC 
and other carcinoma models, thereby focusing on studies in 
which molecular mechanisms involved in radio-
/chemoresistance have been addressed. It will present 
unpublished results from functional studies in preclinical 
models in which we are evaluating the mode of interaction of 
distinct genetic variants with radio-/chemoresistance. 
Concepts of how to integrate the results from NGS into novel 
personalized treatment strategies for HNSCC will be 
discussed. 
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Massive parallel sequencing technologies (also: next 
generation sequencing) have revolutionized our 
understanding of the genomic and transcriptional makeup of 
malignomas. Aided by equally impressive developments in 
sequencing- and chip-based epigenetic tumor profiling and 
developments in mass spectrometry which allow for a 
comprehensive proteomic and metabolomic profiling we are 
now able to draw fairly comprehensive multi –omics 
landscapes of individual tumors both from tissue but 
increasingly also from blood or circulating tumor cells. 
However, many issues remain still challenging when it comes 
to a translation of these findings into a potential clinical 
outreach. This includes matters of tumor heterogeneity 
specifically with respect to tumor evolution in the metastatic 
setting as well as under therapeutic pressure. Other widely 
unresolved issues include the usefulness of identified drivers 
as novel targets for therapy or as predictive biomarkers and 
strategies to implement broad high throughput genomic 
testing into individualized patient care. Specifically the 
latter issue will decide which of these multi–omics 
technologies will take the step from tools merely for 
biological research profiling to advanced and modern routine 
clinical care. 
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Gene expression profiles hold great promises for PRO 
(Personalized Radiation Oncology), yet very few - if any - are 
implemented in routine clinical practice and used as 
predictive biomarkers for treatment decisions in radiation 
oncology. 
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Several challenges needs to addressed before a gene 
expression profile can be approved as a predictive biomarker 
by regulatory bodies like the European Medicines Agency 
(EMA) and the US Food and Drug Administration (FDA). In an 
ongoing trial, EORTC-1219 (ClinicalTrials.gov ID: 
NCT01880359), a 15-gene hypoxia profile (1,2) is being tested 
prospectively. One of the primary aims of the study is to 
provide data for regulatory approval of the gene profile as an 
accompanying biomarker for the use of the hypoxia modifier 
Nimorazole. 
The development and ongoing validation of this 15-gene 
profile will be used as a general example of the challenges 
for implementing gene expression profiles in PRO. Different 
strategies for identification of relevant gene expression 
profiles will be discussed together with the challenges of 
validating the predictive value of a gene expression profile. 
The requirements for a quick and robust test for the gene 
expression profile working on simple routine FFPE (formalin-
fixed, paraffin-embedded) sections will also be discussed. 
Finally, some of the regulatory and patent issues related to 
gene expression profiles will be commented upon. 
1. Toustrup et al. Cancer Res. 71(17):5923-31, 2011. 
2. Toustrup et al. Radiother Oncol 102(1):122-9, 2012. 
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A key challenge in radiotherapy is to maximise radiation 
doses to cancer while minimising damage to surrounding 
healthy tissues. As toxicity in a minority of patients limits the 
doses that can be safely given to the majority, there is 
interest in developing a test to measure an individual’s 
radiosensitivity before treatment and predict their likelihood 
of developing toxicity. A biomarker that predicts a cancer 
patient’s risk of toxicity could be used to personalise dose 
prescriptions or to offer alternative treatments. Many 
approaches have been studied to measure radiosensitivity. 
The development of omics technologies underpinned genome 
wide association studies (GWAS) attempting to identify 
genetic variants reported as single nucleotide polymorphisms 
(SNPs). The advantages of the approach include: a genetic 
test will be easier to implement clinically than a functional 
assay; a genetic test will not suffer from the poor 
reproducibility associated with some radiosensitivity testing 
methods; and SNPs are the most common type of genetic 
variation and so easiest to identify. Omics technologies offer 
promise, but to have an impact on radiotherapy practice 
research must identify biomarkers that replicate across 
cohorts. Robust replication needs big data, which is only 
possible with large collaborative efforts. The need for big 
data was addressed by establishing an international 
Radiogenomics Consortium. Achievements of the consortium 
include: pooling cohorts to increase statistical power and 
identify definitively whether individual SNPs are associated 
with risk of toxicity; producing guidelines to improve the 
reporting of radiogenomics studies; identifying approaches 
for analysing data from heterogeneous cohorts involving 
different toxicity reporting scales and treatment regimens; 
and establishing studies collecting standardised data to 
improve our ability to detect more SNPs. Work over the past 
three years showed it is possible to pool heterogeneous 
cohorts and has identified several SNPs associated with risk 
of toxicity. Large collaborative projects in the cancer pre-
disposition field involving analysis of ~100,000 participants 
shows that sufficient SNPs can be identified to generate a 
polygenic risk profile for clinical implementation. For 
example, men in the top 1% of the distribution of a 74-SNP 
polygenic risk score have a 4.7 fold increased risk of 
developing prostate cancer. Key challenges for the radiation 
oncology community are to collect the data in multiple 
cancers to identify enough SNPs to generate a polygenic risk 
profile and to increase understanding of the need for 
endpoint dependent versus independent profiles. 
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Personalized Radiation Oncology (PRO) integrating omics 
technology is a rapidly developing concept that will have an 
enormous impact on oncologic treatments and specifically 
radiation therapy in the near future. Tumor behaviour and 
outcomes related to oncologic treatments are related to 
several factors of which connections are nowdays poorly 
known. Different branches of medicine have developed their 
own lines of research which are sometimes difficult to be 
interpreted, difficult to be integrated with classical clinical 
factors and for these reasons, difficult to be applied in 
clinical practice. In clinical prediction and decision making 
process, results provided by omics are rarely used, whereas 
clinicians usually use clinical and imaging data for 
understanding tumor behaviour, predicting patients' 
outcomes and for choosing the the most suitable treatment. 
The clinical decision is usually based on general guidelines 
which extrapolate information from randomized clinical trial. 
Moreover independent factors derived from several RCT are 
used by the Radiation Oncologist to make his prevision on 
tumor behaviour and consequently to choose the „right 
treatment“ for a specific patient. Randomized clinical trials 
enclose patients with characteristics chosen beforehand and 
usually omics informations are rarely or never included. This 
lead to a potential missing of several information that could 
refine prediction and thus promote personalized treatments 
and to an erroneous outcomes prediction that can lead to un-
appropriate treatment decision for a specific patient. 
Integrative data analysis has the potential to correlate data 
of different origins (genetic, radiology, clinic...) with 
patient’s outcomes and to create a consistent dataset useful 
to obtain a trustful analysis for the Decision Support System. 
The DSS can easily be applied in clinical practice helping the 
Radiation Oncologist to utilize several information that 
otherwise would be excluded in the process of decision 
making. The possibility to predict the outcome for a certain 
patient in combination with a specific treatment with more 
accuracy, will lead to better identification of risk groups and 
thus better treatment decisions in individual patients, but it 
will also stimulate research focused on specific risk groups 
which try to find new treatment options or other 
combinations of treatment options for these subgroups. 
These treatments will be more personalized, which will not 
only save patients from unnecessary toxicity and 
inconvenience, but will also facilitate the choice of the most 
appropriate treatment . The resulting predictive models, 
based on patient features, enable a more patient specific 
selection from the treatment options menu and a possibility 
to share decisions with patients based on an objective 
evaluation of risks and benefits. Finally, considering the 
important role that predictive models could play in the 
clinical practice, clinicians must be aware of the limits of 
these prediction models. They need to be internally validated 
taking into account the quality of the collected data. An 
external validation of models is also essential to support 
general applicability of the prediction model. Therefore 
structural collaboration between different groups is crucial to 
generate enough anonymized large databases from patients 
included or not in clinical trials.  
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